New research from the University of Oklahoma, published today in Cancer Cell, describes for the first time a "triangle ...
Consistent Improvements in Weight Gain, Lean Body Mass, and Activity were Observed Across Treated Patients including +6.4% Mean Weight Gain at 12 Weeks vs −5.4% Mean Weight Loss on Placebo The Phase 2 ...
SOLANA BEACH, Calif., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (ARTL) (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to ...
Hosted on MSN
Artelo’s cancer cachexia drug succeeds in Phase II
Artelo Biosciences’ cancer anorexia-cachexia syndrome (CACS) drug has helped patients gain weight in a Phase II trial. During the CAReS study (EudraCT-2020-000464-27), ART27.13, a cannabinoid receptor ...
Cachexia is a common complication of cancer and is associated with an increased risk of death. The level of growth differentiation factor 15 (GDF-15), a circulating cytokine, is elevated in cancer ...
Patients treated with ART27.13 showed consistent improvements in weight, lean body mass, and activity While clinical benefits were observed in all treated cohorts, the best outcomes in CAReS were ...
Cancer cachexia is a complex metabolic syndrome characterized by the ongoing loss of skeletal muscle mass, with or without fat loss, that cannot be reversed entirely by conventional nutritional ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results